Artia Global Partners
Latest statistics and disclosures from Artia Global Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, NVO, VKTX, ITCI, AZN, and represent 67.62% of Artia Global Partners's stock portfolio.
- Added to shares of these 10 stocks: LLY (+$13M), SLNO (+$9.1M), NVO (+$6.0M), VKTX (+$5.1M), RVMD, NUVL, MRUS, CNTA, ALEC, CRBP.
- Started 7 new stock positions in CNTA, NUVL, SLRN, RVMD, SMMT, ALEC, QTTB.
- Reduced shares in these 10 stocks: Lilly Eli & Co option (-$68M), , Novo-nordisk A S option (-$44M), Viking Therapeutics Inc call (-$8.0M), Insmed (-$7.4M), OCUL, APGE, CRNX, IONS, PLRX.
- Sold out of its positions in APGE, Insmed, Lilly Eli & Co option, MRK, Novo-nordisk A S option, OCUL, PLRX, SRPT, Viking Therapeutics Inc call.
- Artia Global Partners was a net seller of stock by $-147M.
- Artia Global Partners has $367M in assets under management (AUM), dropping by -29.08%.
- Central Index Key (CIK): 0001937964
Tip: Access up to 7 years of quarterly data
Positions held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Artia Global Partners
Artia Global Partners holds 44 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 26.0 | $95M | +16% | 108k | 885.94 |
|
| Novo-nordisk A S Adr (NVO) | 24.1 | $88M | +7% | 742k | 119.07 |
|
| Viking Therapeutics (VKTX) | 9.2 | $34M | +17% | 533k | 63.31 |
|
| Intra Cellular Therapies (ITCI) | 4.3 | $16M | 217k | 73.17 |
|
|
| Astrazeneca Sponsored Adr (AZN) | 4.1 | $15M | 191k | 77.91 |
|
|
| Soleno Therapeutics (SLNO) | 3.8 | $14M | +190% | 274k | 50.49 |
|
| Alnylam Pharmaceuticals (ALNY) | 2.6 | $9.6M | 35k | 275.03 |
|
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.4 | $8.8M | 19k | 465.08 |
|
|
| Vaxcyte (PCVX) | 2.4 | $8.7M | 76k | 114.27 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 2.2 | $8.2M | 15k | 542.08 |
|
|
| Axsome Therapeutics (AXSM) | 2.2 | $7.9M | 88k | 89.87 |
|
|
| Protagonist Therapeutics (PTGX) | 1.5 | $5.6M | 124k | 45.00 |
|
|
| Neurocrine Biosciences (NBIX) | 1.4 | $5.2M | 45k | 115.22 |
|
|
| Revolution Medicines (RVMD) | 1.2 | $4.3M | NEW | 96k | 45.35 |
|
| Dyne Therapeutics (DYN) | 1.2 | $4.3M | 120k | 35.92 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 1.2 | $4.3M | +13% | 149k | 28.77 |
|
| Merus N V (MRUS) | 1.1 | $4.0M | +59% | 80k | 49.96 |
|
| Insmed Com Par $.01 (INSM) | 1.1 | $3.9M | 53k | 73.00 |
|
|
| Celldex Therapeutics Com New (CLDX) | 0.7 | $2.6M | 75k | 33.99 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 0.6 | $2.3M | -46% | 46k | 51.10 |
|
| Ideaya Biosciences (IDYA) | 0.5 | $2.0M | +15% | 63k | 31.68 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.5 | $1.7M | 421k | 4.11 |
|
|
| Springworks Therapeutics (SWTX) | 0.5 | $1.7M | 54k | 32.04 |
|
|
| Nuvalent Inc-a (NUVL) | 0.4 | $1.6M | NEW | 15k | 102.30 |
|
| Xenon Pharmaceuticals (XENE) | 0.4 | $1.6M | 40k | 39.37 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.4 | $1.3M | NEW | 80k | 15.99 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.3 | $1.2M | +53% | 156k | 7.99 |
|
| Charles River Laboratories (CRL) | 0.3 | $1.2M | -8% | 6.3k | 196.97 |
|
| Ionis Pharmaceuticals (IONS) | 0.3 | $1.2M | -51% | 31k | 40.06 |
|
| Keros Therapeutics (KROS) | 0.3 | $1.2M | 20k | 58.07 |
|
|
| Kura Oncology (KURA) | 0.3 | $1.1M | 57k | 19.54 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.3 | $1.1M | 7.4k | 149.31 |
|
|
| Annexon (ANNX) | 0.3 | $1.0M | +16% | 172k | 5.92 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.3 | $978k | +137% | 47k | 20.63 |
|
| Silence Therapeutics Ads (SLN) | 0.3 | $954k | 53k | 18.18 |
|
|
| Syndax Pharmaceuticals (SNDX) | 0.3 | $929k | 48k | 19.25 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.2 | $901k | 54k | 16.60 |
|
|
| Alector (ALEC) | 0.2 | $901k | NEW | 193k | 4.66 |
|
| Disc Medicine (IRON) | 0.2 | $660k | 13k | 49.14 |
|
|
| Larimar Therapeutics (LRMR) | 0.2 | $593k | 91k | 6.55 |
|
|
| Acelyrin (SLRN) | 0.1 | $459k | NEW | 93k | 4.93 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.1 | $330k | 1.6k | 212.22 |
|
|
| Summit Therapeutics (SMMT) | 0.1 | $318k | NEW | 15k | 21.90 |
|
| Q32 Bio (QTTB) | 0.1 | $210k | NEW | 4.7k | 44.62 |
|
Past Filings by Artia Global Partners
SEC 13F filings are viewable for Artia Global Partners going back to 2022
- Artia Global Partners 2024 Q3 filed Nov. 14, 2024
- Artia Global Partners 2024 Q2 filed Aug. 14, 2024
- Artia Global Partners 2024 Q1 filed May 15, 2024
- Artia Global Partners 2023 Q4 filed Feb. 14, 2024
- Artia Global Partners 2023 Q3 filed Nov. 14, 2023
- Artia Global Partners 2023 Q2 filed Aug. 14, 2023
- Artia Global Partners 2023 Q1 filed May 15, 2023
- Artia Global Partners 2022 Q4 filed Feb. 14, 2023